The 5th Annual EC21 BioVentures Conference, to be held March 22-23 in London, will showcase public and private biotechnology companies from across the world. Offering an opportunity to network with recognised leading industry figures, delegates will also be able to attend sessions giving an overview of the current status of the industry and offering insight into future opportunities within this specialised sector.
INFO SOURCES
EC21 BioVentures
About EC21:
Presenters so far include: Ablynx, ACE BioSciences, Affymax, Inc., Ambit Biosciences, Atugen AG, Austrianova Biotechnology, Avidex, BioVex Limited, BioXell SpA, DIREVO Biotech AG, ESBATech AG, Favrille, Inc., InNexus Biotechnology Inc., Intercell AG, KAI Pharmaceuticals, Inc., Lectus Therapeutics Ltd, Metabometrix Limited, MNLpharma Ltd., Morphotek, Inc., NeuroSearch A/S, NOXXON Pharma AG, OctoPlus, Oncolytics Biotech Inc., Oxford Genome Sciences, PIramed Ltd., Remergent, Inc., Scil Technology GmbH, Sidec Technologies AB, Synexa Life Sciences, Thiakis Limited, Trigen Ltd, Xanthus Life Sciences, and YM BioSciences Inc.
Sponsors: Burrill & Company, Dresdner Kleinwort Wasserstein, EuropaBio, and London Development Agency (BioLondon), and London Stock Exchange.
Supporters: 3i, Apax Partners, Atlas Ventures, BioMedinvest AG, BioWorld Today, Business Wire, Capital MS&L, De Facto Communications plc, DVC Deutsche Venture Capital, Earlybird, Ferghana Partners Group, F&C, HBM Partners, Index Ventures, Investor Growth Capital, Lehman Brothers, Nomura, Quest Management NV, Red Herring, Techno Venture Management, and Warburg Pincus.
Supporting Material
